Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News


Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
11/16/2013 | 03:34am CEST

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news
Date Title
06:03a ELBIT : New Cyberbit Range Release Offers Hyper-Realistic Training for Multidimensional Approach to Cyberdefense
06:03a MCAFEE LABS : Liquidity Trumps Longevity in Market for Stolen Medical Records
06:01a PETROCELTIC RESOURCES : Notification of major interest in shares
06:01a PETROCELTIC RESOURCES : Result of General Meeting – 20 October 2016
06:01a ACCI AUSTRALIAN CHAMBER OF COMMERCE & INDUSTRY : New research shows backpacker tax will overshoot revenue target
06:01a REDFLOW : Vic, NSW gas bans’making SA issue worse’
05:56a MGC PHARMACEUTICALS : Annual Report 2016
05:56a BLINA MINERALS NL : 26 Oct 2016 Notice of Annual General Meeting and Proxy Form
05:51a REDFLOW : Conservation SA conserving energy with ZCell battery installation
05:51a MINISTRY OF AGRICULTURE OF PEOPLE REPUBLIC O : 3rd Open Science Meeting of Global Land Project held in Beijing
Latest news
Hot News 
0.02%Oil Prices Down on U.S. Crude Stock Growth and OPEC Uncertainty
Most Read News
10/25 SAMSUNG ELECTRONICS : Apple's holiday surprise - big sales, not so big profits
10/25 CBS : Redstone sues ex-girlfriends, says had to borrow from National Amusements
10/25 A BAT deal with Reynolds adds to Big Tobacco's e-cig advantage
10/25 AMERICAN MANGANESE : Annual general meeting results
10/25 GCP Applied Technologies Celebrates 30 Years in China
Most recommended articles
10/25DJNEWS HIGHLIGHTS : Top Global Markets News of the Day
10/25 DEUTSCHE BANK : Schaeuble says monetary policy has reached its limits
10/25 APPLE : Gadgets in decline as R&D shifts to software and services - study
10/24DJGold Prices Turn Lower Amid Strong Economic Data